Serum Institute’s COVID-19 vaccine Covovax has been recommended to the Standing Technical Sub Committee (STSC) of the National Technical Advisory Group on Immunization (NTAGI) for inclusion of use in the 12-17 years age group in the national COVID-19 vaccination program.
Confirming this latest move, health officials said that a meeting of the COVID-19 working group of the NTAGI took place on April 1 during which data of Covovax was reviewed. After this, it was recommended that the vaccine can be included in the national COVID-19 vaccination programme for inoculating those aged 12 years and above.
India’s drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12-17 age group, subject to certain conditions, on March 9.
